BioLineRX
BLRX
12 hedge funds and large institutions have $8.01M invested in BioLineRX in 2013 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
57% more capital invested
Capital invested by funds: $5.12M → $8.01M (+$2.89M)
20% more funds holding
Funds holding: 10 → 12 (+2)
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Senvest Management
New York
|
+$105K |
| 2 |
UBS AM
Chicago,
Illinois
|
+$80.6K |
| 3 |
ARTA
A.R.T. Advisors
New York
|
+$27.4K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$22.6K |
| 5 |
VKH
Virtu KCG Holdings
New York
|
+$6.45K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$537K |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$163K |
| 3 |
Renaissance Technologies
New York
|
-$139K |
| 4 |
Citigroup
New York
|
-$1.61K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $3.19M | -$537K | -333 | -15% |
|
|
OM
2
Opaleye Management
Boston,
Massachusetts
| $2.07M | +$1.91M | +1,188 | New |
|
|
SM
3
Senvest Management
New York
| $2.05M | +$105K | +65 | +6% |
|
|
4
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $405K | -$163K | -101 | -30% |
|
|
5
UBS AM
Chicago,
Illinois
| $85K | +$80.6K | +50 | New |
|
6
Bank of New York Mellon
New York
| $50K | – | – | – |
|
|
VKH
7
Virtu KCG Holdings
New York
| $37K | +$6.45K | +4 | +22% |
|
8
Royal Bank of Canada
Toronto,
Ontario, Canada
| $34K | – | – | – |
|
|
9
Renaissance Technologies
New York
| $29K | -$139K | -86 | -83% |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $28K | +$22.6K | +14 | +467% |
|
|
ARTA
11
A.R.T. Advisors
New York
| $28K | +$27.4K | +17 | New |
|
12
Wells Fargo
San Francisco,
California
| $3K | – | – | – |
|
|
13
Citigroup
New York
| – | -$1.61K | -1 | Closed |
|
BLRX Hedge Fund Activity: Q4 2013 in Review
12 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in BioLineRX (BLRX) for Q4 2013, worth a combined $8.01M — up 57% from $5.12M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new BLRX positions and 1 closed out — a net gain of 2 holders — while 3 added to existing stakes and 3 trimmed.
The largest buyer was Senvest Management, adding an estimated $105K. The largest seller was OrbiMed, cutting an estimated $537K.
- 12 institutional investors held BioLineRX (BLRX) as of Q4 2013, up from 10 in Q3 2013.
- Funds reported $8.01M of BioLineRX stock for Q4 2013, up 57% quarter-over-quarter.
- 3 funds opened new BioLineRX positions in Q4 2013 and 1 closed out, a net change of +2 holders.
- The largest BioLineRX buyer in Q4 2013 was Senvest Management, an estimated $105K added.
- The largest BioLineRX seller in Q4 2013 was OrbiMed, an estimated $537K sold.
Based on aggregated 13F filings for Q4 2013.